Shandong Sito Bio-technology Co Ltd (300583) - Total Liabilities
Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) has total liabilities worth CN¥1.06 Billion CNY (≈ $155.82 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Shandong Sito Bio-technology Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Shandong Sito Bio-technology Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Shandong Sito Bio-technology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300583 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Shandong Sito Bio-technology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Sito Bio-technology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangzhou Echom Sci&Tech Co Ltd
SHE:002420
|
China | CN¥1.70 Billion |
|
JiangXi BaiSheng Intelligent Technology Co. Ltd.
SHE:301083
|
China | CN¥197.64 Million |
|
Pollard Banknote Limited
TO:PBL
|
Canada | CA$315.29 Million |
|
HCK Capital Group Bhd
KLSE:7105
|
Malaysia | RM782.44 Million |
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
USA | $18.70 Million |
|
CHEERWIN GRP. -0000002
F:1RQ
|
Germany | €624.31 Million |
|
Suzhou Longjie Special Fiber Co Ltd
SHG:603332
|
China | CN¥246.68 Million |
|
CPH Chemie und Papier Holding
SW:CPHN
|
Switzerland | CHF164.99 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Shandong Sito Bio-technology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shandong Sito Bio-technology Co Ltd (300583) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Sito Bio-technology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Sito Bio-technology Co Ltd (2012–2024)
The table below shows the annual total liabilities of Shandong Sito Bio-technology Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.14 Billion ≈ $167.06 Million |
-2.82% |
| 2023-12-31 | CN¥1.17 Billion ≈ $171.91 Million |
-4.04% |
| 2022-12-31 | CN¥1.22 Billion ≈ $179.15 Million |
-1.09% |
| 2021-12-31 | CN¥1.24 Billion ≈ $181.11 Million |
+7.63% |
| 2020-12-31 | CN¥1.15 Billion ≈ $168.27 Million |
+4.49% |
| 2019-12-31 | CN¥1.10 Billion ≈ $161.04 Million |
+50.21% |
| 2018-12-31 | CN¥732.63 Million ≈ $107.21 Million |
+130.81% |
| 2017-12-31 | CN¥317.42 Million ≈ $46.45 Million |
-4.74% |
| 2016-12-31 | CN¥333.22 Million ≈ $48.76 Million |
+0.48% |
| 2015-12-31 | CN¥331.62 Million ≈ $48.53 Million |
+53.30% |
| 2014-12-31 | CN¥216.31 Million ≈ $31.65 Million |
+93.44% |
| 2013-12-31 | CN¥111.83 Million ≈ $16.36 Million |
+306.45% |
| 2012-12-31 | CN¥27.51 Million ≈ $4.03 Million |
-- |
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more